□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□Masuo KONDOH 1）生体バリアに着目した創薬・RS 研究□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□2）生体バリアに着目した DDS・RS 研究（中枢神経疾患）□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□3）生体バリアに着目した DDS・RS 研究（患者フレンドリー投与技術）□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□4）革新的創薬マテリアルの臨床開発・RS 研究□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□教 授 近藤 昌夫 Professor 06-6879-8195 masuo@phs.osaka-u.ac.jp教授 近藤 昌夫1. Ishimoto et al., Japanese regulatory considerations for interoperability of medical devices. Ther Innov Regul Sci, 2023, 57, 104-108.2. Fujiwara-Tani et al., Claudin-4: A new molecular target for epithelial cancer therapy. Int J Mol Sci, 2023, 24, 5494.3. Kurauchi et al., A Japanese concept of considerations for evaluation of dental materials for tooth bleaching. J Dent Sci Rev, 2023, 59, 23-27.4. Shirasago et al., A single mutation in the E2 glycoprotein of hepatitis C virus broadens the claudin specificity for its infection, Sci Rep, 2022, 12, 20243.5. Bai et al., A doxycycline-inducible CYP3A4-Caco-2 cell line as a model for evaluating safety of aflatoxin B1 in the human intestine, Toxiocol Lett, 2022, 370, 1-6.6. Hashimoto et al., SARS-CoV-2 disrupts respiratory vascular barriers by suppressing claudin-5 expression, Sci Adv, 2022, 8, eabo6783.7. Noguchi et al., Safety evaluation of MA-T after ingestion in mice. Toxicology, 2022, 477, 153254.8. Maesaka et al., Hypomethylation of CLDN4 gene promoter is associated with malignant phenotype in urinary bladder cancer. Int J Mol Sci, 2022, 23, 6516.9. Watari et al., Homoharringtonine is a transdermal granular permeation enhancer. Biochem Biophys Res Commun, 2022, 616, 140-144.10.Wakayama et al., Modifying the blood–brain barrier by targeting claudin-5; safety and risks. Ann NY Acad Sci, 2022, 14, 62-69.□□□□□□□□□□□□□□Regulatory Science for Development of New Drugs, Medical Devices, and Regenerative Medicinal Products
元のページ ../index.html#21